SCHEMBL679707

SCHEMBL679707

c1ccc(-c2cscn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.47
RAB9A P51151 5/20 0.46
NPC1 O15118 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 3/20 0.46
METAP2 P50579 2/20 0.46
METAP1 P53582 2/20 0.46
CYP3A4 P08684 2/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CYP2D6 P10635 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
FKBP1A P62942 1/20 0.46
HIF1A Q16665 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
KAT6A Q92794 1/20 0.46
GRM5 P41594 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL27495181 0.98 ALDH1A1 (0.47) SCN9ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL27732241 0.88 KAT6A (0.49) SCN9ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL4640169 0.88 TSHR (0.59) SCN9ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL16159517 0.85 NPC1 (0.41) SCN9ARAB9ANPC1SMN1; SMN2KDM4E
Oxamate SCHEMBL9830672 0.85 KAT6A (0.47) SCN9AKDM4EMETAP1KAT6AALDH1A1
SCHEMBL7492735 0.84 KAT6A (0.43) SCN9ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL16159141 0.84 SCN9A (0.42) SCN9ARAB9ANPC1SMN1; SMN2KDM4E
Quinoline SCHEMBL27587533 0.82 ALDH1A1 (0.55) SCN9ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL8944146 0.82 METAP2 (0.40) SCN9ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL16159656 0.81 METAP2 (0.40) SCN9ARAB9ANPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048071-A1 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS Cadrenal Therapeutics, Inc. 2026-02-19 US claimed
US-20260027123-A1 Compositions for Modulating Lipoxygenase and Methods of Using Same UNIV CALIFORNIA (US) 2026-01-29 US claimed
EP-4615432-A2 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS Veralox Therapeutics Inc. (US) 2025-09-17 EP claimed
EP-4612135-A1 ORAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES Veralox Therapeutics Inc. (US) 2025-09-10 EP claimed
EP-4558508-A1 COMPOSITIONS FOR MODULATING LIPOXYGENASE AND METHODS OF USING SAME The Regents of the University of California (US) 2025-05-28 EP claimed
CN-120040505-A Phosphorus phenol ligand, phosphorus phenol complex, preparation method and application thereof, and ethylene polymerization method 南开大学 2025-05-27 CN claimed
CN-119192699-A Latex composite resin composition for 3D printing and preparation method and application thereof 中国科学院福建物质结构研究所 2024-12-27 CN claimed
CN-118976027-A Application of aminothiazole derivative in preparation of medicine for treating neurodegenerative diseases 武汉亿诺药业有限公司 2024-11-19 CN claimed
CN-118903136-A Application of aminothiazole compound in preparation of medicine for treating xerophthalmia and medicine composition 武汉亿诺药业有限公司 2024-11-08 CN claimed
WO-2024103023-A2 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS VERALOX THERAPEUTICS (US) 2024-05-16 WO claimed
JP-2005533066-A 2005-11-04 JP claimed
EP-1527070-A1 AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2005-05-04 EP claimed
WO-2003106455-A1 AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-12-24 WO claimed
US-5142545-A LASER DYE LAMBDA PHYSIK GESELLSCHAFT ZUR HERSTELLUNG VON LASERN MBH (DE) 1992-08-25 US claimed
EP-0263020-B1 4-PHENYL THIAZOLE DERIVATIVES LABORATOIRE L. LAFON Société anonyme dite: (FR) 1990-07-25 EP claimed
US-4891305-A LASERS RICOH CO., LTD. (JP) 1990-01-02 US claimed
US-4847274-A CENTRAL NERVOUS SYSTEM, SEDATIVES LABORATOIRE L. LAFON (FR) 1989-07-11 US claimed
EP-0263020-A1 4-Phenyl thiazole derivatives LABORATOIRE L. LAFON Société anonyme dite: (FR) 1988-04-06 EP claimed
US-4102688-A CONTAINING PYRAZOLO(3,4-B)PYRIDINE/3,6-DIONE MOIETY FUJI PHOTO FILM CO., LTD. (JP) 1978-07-25 US claimed
US-3970461-A Fogged, direct-positive silver halide emulsion containing carbocyanine dye having indolenine nucleus FUJI PHOTO FILM CO., LTD. (JA) 1976-07-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048071-A1 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS ALOX12, ALOX5, ALOX15 SCN9A 4039/4885RAB9A 4472/4885NPC1 2086/4885
US-20260027123-A1 Compositions for Modulating Lipoxygenase and Methods of Using Same ALOX12, ALOX15, ALOX15B SCN9A 3669/4885RAB9A 4241/4885NPC1 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.